Amicus opens UCity R&D tower, calls Philly the ‘Cradle of Cures’

The future of research and development, in rare diseases and beyond, is Philadelphia.

By moving its R&D team to University City this year, publically traded gene therapy company Amicus Therapeutics now calls the Greater Philadelphia region’s bustling cell and gene therapy ecosystem home.

Article from the Philadelphia Inquirer

This isn’t a ‘biotech bubble,’ it’s ‘Philadelphia’s moment’ to become a center for gene therapy, says Penn-based CEO

“This is not a bubble, it’s Philadelphia’s moment,” Steven Nichtberger, CEO of Cabaletta Bio offers his perspective on the region’s exponential growth as the epicenter of cell and gene therapy.

Article from the Philadelphia Inquirer

PACT 2019 Philadelphia Venture Report

PACT Philadelphia’s annual report ranks the region seventh in the country for VC funding after a record-setting $2.5 billion invested in 2019, fueled by a steady stream of life sciences deals and activity among cell and gene therapy and connected health companies.

Report from PACT

Biotech Tour: Inside the Newly Rehabbed Spring House Innovation Park

See inside the new Spring House Innovation Park, a soon-to-be hub of life sciences innovation housing companies like Anpac Bio – which will open its U.S. HQ and very first east coast clinical lab site on the campus.

Article from Philadelphia magazine

A cell and gene therapy development center is taking 680K square feet at KOP’s Discovery Labs

New York-based Deerfield Management and King of Prussia’s The Discovery Labs will open the Center for Breakthrough Medicines, occupying 680,000 square feet of The Discovery Labs space to provide pre-clinical through commercial manufacturing of cell and gene therapies, adding to our rich ecosystem as a cell and gene therapy hub.

Article from Technical.ly

Roche completes $4.3B purchase of Philadelphia gene therapy pioneer Spark Therapeutics

Roche completes its $4.3 billion purchase of our region’s own Spark Therapeutics in a historic acquisition. This is a milestone achievement for Greater Philadelphia as an epicenter of talent, research and results in gene therapy.

Article from the Philadelphia Business Journal

Penn Medicine’s Jonathan Epstein Receives Prestigious National Award from American College of Physicians

National recognition for Penn Medicine’s Jonathan Epstein, MD, who will receive the prestigious Harriet P. Dustan Award for Outstanding Work in Science as Related to Medicine from the American College of Physicians.

Article from Penn Medicine

Top 25 Biotech Companies of 2019

Companies with Greater Philadelphia regional ties including Incyte, WuXi AppTec, and CSL are ranked among top 25 biotech companies of 2019.

Article from Genetic Engineering & Biotechnology News

Roche Agrees to buy Spark Therapeutics for $4.3 billion

Roche Holding AG has agreed to purchase Spark Therapeutics Inc for $4.3 billion.

Spark, which was founded by the Children’s Hospital of Philadelphia, will continue to operate in Philadelphia as an independence company under Roche.

“With its worldwide reach and extensive resources, Roche will help us accelerate the development of more gene therapies for more patients for more diseases,” Spark CEO Jeffrey D. Marrazzo said in a joint statement issued with Roche.

The CHOP Foundation will collect about $430 million for its Spark shares.

Article by the Philadelphia Inquirer

New South Philadelphia Offices Planned for California-based Iovance

The California-based Iovance Biotherapeutic is expanding to the Philadelphia Navy Yard in South Philadelphia to build a 136,000 square foot office, lab, and production facility.

“We know there are certainly trained employees in the region who have worked in cell therapy and have deep roots in cell therapy,” said Maria Fardis, the president and chief executive of Iovance.

Iovance specializes in the development and commercialization of cancer immunotherapies using cells known as tumor-infiltrating lymphocytes.

Construction for the $125 million facility is expected to last two years. Iovance plans to employ several hundreds of people while producing treatments for thousands of patients globally.

Article by the Philadelphia Inquirer